Rivaroxaban is a direct inhibitor of the coagulation factor Xa with anticoagulant activity.653 Since COVID-19 is associated with both venous and arterial thrombotic complications, prophylactic anticoagulation is widely recommended for hospitalized patients with COVID-19.654 Thus, several phase III/IV clinical trials have evaluated its anticoagulant ability in COVID-19 patients. The gene discussed is F10; the disease is COVID-19.